Hims Hers Health Inc

Dick's Sporting Goods shares fell 18.23% in premarket trading Tuesday after the retailer missed quarterly estimates and issued a cautious full-year outlook amid a promotional sporting goods backdrop. Comparable sales rose 4.9%, helped by broad-based category growth including strong results from the 2026 FIFA World Cup, while Foot Locker's pro forma comparable sales fell 3.6%. Meta Platforms gained 0.66% premarket on a report that it plans to launch a consumer-facing AI agent in the coming weeks and a new AI model in October. Johnson & Johnson rose 0.49% after the FDA approved a label expansion for its myasthenia gravis therapy Imaavy as a treatment for warm autoimmune hemolytic anemia, potentially making it the first U.S.-approved therapy for wAIHA. Hims & Hers Health edged up 0.26% premarket after tumbling over 8% Monday on reports that Visa will impose nearly $75,000 in penalties in September after thousands of credit card dispute complaints tied to weight-loss subscriptions triggered its inclusion in Visa's Acquirer Monitoring Program.

Hims & Hers Health shares fell about 8% Monday after reports that Visa placed the telehealth company under a monitoring program tied to customer payment disputes. The action followed an increase in card chargebacks linked to Hims' weight-loss subscription business during July, and the company could face fees of nearly $75,000 in September based on an $8 charge for each dispute. To leave the program, Hims would need to keep its dispute rate below 1.5% of transactions for three consecutive months, and payment processor Stripe reportedly notified the company of the move earlier this month. The development adds another challenge as Hims' subscription practices face regulatory scrutiny, with the Federal Trade Commission and state authorities suing the company in July over allegations involving billing, cancellations and customer data. Hims has disputed the allegations and said it has taken steps to address customer payment concerns.

Hims & Hers Health shares fell 9.2% in afternoon trading after Bloomberg reported that Visa enrolled the telehealth company in its Acquirer Monitoring Program following a surge in customer credit card disputes in its weight-loss subscription business. The company faces an estimated $75,000 penalty after dispute rates exceeded acceptable limits, though a spokesperson said the company has seen a relatively small number of disputed charges and that checkout is clear about membership and medication costs. The billing scrutiny follows a recent FTC update alleging deceptive billing and cancellation practices, claims the company has stated it will vigorously defend against. The stock closed at $31.02, down 8.3% from the previous close.

Hims & Hers Health is facing legal pressure after the Federal Trade Commission and state regulators filed a civil enforcement action, followed by a consumer class action targeting the company's telehealth privacy and subscription practices. The stock closed at $33.78, with a 1-day return of 6.03% and a 7-day return of 20.00%, though the 1-year total shareholder return is down 24.21%. The most followed narrative pegs fair value at $173.02, implying the stock is 80.5% undervalued, based on aggressive growth assumptions including faster revenue growth than the 15.7% annual consensus forecast and a future P/E multiple of 60x. However, the upbeat narrative could crack if regulatory actions escalate or subscriber growth falls short of expectations.

Hims & Hers Health and Novo Nordisk both saw their shares drop after reporting strong growth, as investors focused on rising costs in the weight-loss pill market. Hims & Hers posted second-quarter revenue of $753.2 million, up 38% and above the $699 million analysts expected, and raised its full-year revenue outlook to $3.1 billion to $3.3 billion, but swung to a $127.9 million net loss from a $43.5 million profit a year earlier. Novo Nordisk raised its annual guidance to a range of adjusted sales and operating profit down 6% to flat, versus a prior range of down 4% to 12%, yet its Wegovy pill sales of 3.22 billion kroner missed the 3.33 billion kroner analysts expected. Hims & Hers shares fell over 2% on Tuesday, while Novo Nordisk shares dropped about 6% a week earlier.

Hims & Hers Health CEO Andrew Dudum defended the company against a Federal Trade Commission lawsuit, saying the agency's decision to sue reflected a desire for publicity rather than a genuine resolution. Dudum told CNBC that the company had worked with the FTC for years and that the agency ultimately wanted a headline more than a real agreement. The FTC, joined by Los Angeles County and Utah, filed the lawsuit in July alleging Hims & Hers shared user health data with advertisers, billed customers before they spoke with a provider, and made cancellations difficult. Dudum also addressed the company's shift away from compounded GLP-1 weight loss drugs toward branded medications, anticipating cash-paying patients will eventually see monthly costs drop to between $40 and $50 from a current range of around $150 to $200. The interview came days after Hims & Hers reported a net loss of $86.3 million in the second quarter of 2026, compared with net income of $42.5 million a year earlier, while revenue rose 38% to $753.2 million and full-year guidance was raised to a range of $3.1 billion to $3.3 billion.

Hims & Hers Health stock declined 3% before trimming losses on Tuesday after the telehealth company reported a second-quarter loss of $0.37 per share, swinging from a profit of $0.17 a share a year earlier. Gross margins fell to 64% from 76%, impacted by a one-time cost of $81 million that included expenses from the acquisition of Australian digital health company Eucalyptus, restructuring tied to a shift in weight-loss strategy, and legal reserves for litigation with the Federal Trade Commission. The FTC filed a lawsuit against the company on July 29, alleging it shared private health data with advertisers Meta and Snap and made subscription cancellations difficult, a claim Hims & Hers has rejected and vowed to fight. Year to date, the stock is down more than 4%.

U.S. stock futures were little changed on Tuesday, as fading hopes for a deal to reopen the Strait of Hormuz kept oil prices elevated, while investors looked ahead to key U.S. inflation data for fresh clues on the Federal Reserve's interest rate path. Riot Platforms shares surged 18.3% in premarket trading after the company landed a $9.1 billion, 20-year AI data center contract with Anthropic, marking one of the largest deals yet to link the cryptocurrency mining industry with the rapidly expanding AI infrastructure market. NIQ Global Intelligence shares surged 15.2% after delivering a broad second-quarter earnings beat and raising its full-year outlook, with adjusted EPS of $0.27 versus a $0.21 consensus and revenue of $1.12 billion edging past expectations of $1.11 billion. On Holding shares fell 15.2% after reporting second-quarter net sales of CHF 850.3 million, below the roughly CHF 881 million analysts had expected, as management pointed to a more difficult consumer environment and higher U.S. tariff costs. Rocket Lab shares dropped 9% despite record second-quarter revenue of $234 million, as third-quarter GAAP gross margin guidance of 29% to 31% came in well below the Street's estimate of about 37.6%. Hims & Hers Health shares fell nearly 7% even after better-than-expected revenue and a raised full-year forecast, as investors focused on profitability pressures from expansion into branded GLP-1 weight-loss drugs and international markets.

Wall Street's main indexes were poised to open higher on Tuesday as investors welcomed a report suggesting the United States and Iran were close to a peace agreement. Pakistan's defence minister told Bloomberg News that signals indicated a deal was near, while Qatar's foreign ministry said Iran-Oman talks were in an advanced stage. Brent crude futures turned lower after hitting one-week highs, having surged 5% on Monday on exchange of demands over the strait. Dow E-minis were up 54 points, S&P 500 E-minis up 11.5 points, and Nasdaq 100 E-minis up 103 points. Hims & Hers Health shed 7.3% after the telehealth company posted a wider-than-expected second-quarter loss.

Several stocks made notable premarket moves on Thursday. Riot Platforms surged nearly 20% after second-quarter revenue of $174.2 million exceeded the $154.3 million FactSet consensus, and the crypto miner announced a 191-megawatt data center lease deal with a Leading Frontier AI Lab. Hims & Hers Health fell 6% after trimming the upper end of its full-year EBITDA outlook and posting a net loss of 37 cents per share for Q2, versus a profit of 17 cents a year earlier. Intel edged lower after upsizing a common stock offering to $20 billion from $15 billion for general corporate purposes. Plug Power rallied 13% on a smaller-than-expected second-quarter loss, while First Solar gained more than 3% after Baird upgraded the stock to outperform and raised its price target to $318, citing a strong utility-scale market. Cardinal Health moved nearly 2% higher as adjusted earnings of $2.60 per share beat the $2.42 estimate, though revenue of $63.67 billion missed the $65.15 billion consensus, and full-year EPS guidance topped expectations.

Lowey Dannenberg P.C. is investigating Hims & Hers Health, Inc. for potential violations of federal securities laws. The investigation follows a July 29, 2026 complaint by the Federal Trade Commission, joined by Utah and California, alleging deceptive practices including charging consumers before provider approval, unauthorized recurring subscriptions, difficult cancellation processes, and sharing sensitive health data with platforms like Meta and Snap. Hims & Hers stock fell $3.05 per share, or approximately 10.40%, during intraday trading on July 29, 2026. The law firm is examining whether the company and its executives provided accurate and complete information to investors.

Kirby McInerney LLP announced an investigation into Hims & Hers Health, Inc. over potential securities fraud. The investigation concerns whether the company or its senior management violated federal securities laws or engaged in unlawful business practices. The probe follows a Federal Trade Commission lawsuit filed on July 29, 2026, accusing Hims of sharing customers' medical information with third-party advertisers, including Meta Platforms. On that news, Hims's stock price fell $4.32 per share, or 14.73%, to close at $25.00. No lawsuit has been filed yet, and the investigation is ongoing.

Hims & Hers Health shares closed at $31.65, down 1.59% from the prior day, underperforming the S&P 500's 0.17% decline. The stock has lost 11.09% over the past month, trailing the Medical sector's 2.54% loss and the S&P 500's 3.52% gain. The company is set to report earnings on August 10, 2026, with analysts expecting an EPS of negative $0.07, a 141.18% drop from the prior-year quarter, on revenue of $690.21 million, up 26.68%. For the full year, the Zacks Consensus Estimates forecast a loss of $0.27 per share and revenue of $2.91 billion, representing changes of negative 150.94% and positive 23.78%, respectively. Hims & Hers Health currently carries a Zacks Rank of 3, or Hold, and trades at a forward P/E of 1206, a significant premium to the industry average of 27.01.

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. on behalf of investors who purchased or acquired its securities and suffered significant losses. The investigation follows a Federal Trade Commission lawsuit filed on July 29, 2026, accusing the company of sharing customers' medical information with third-party advertisers, including Snap and Meta Platforms. Following the FTC's action, Hims & Hers Health's stock price fell over 14%. Investors who experienced losses may have legal rights under federal securities laws.

Hims & Hers Health has become a compelling acquisition target after its stock fell 51% over the past year to $30.82, giving it a $7.2 billion market cap despite 2.6 million subscribers. Amazon ranks as the cleanest fit among potential acquirers, with its pharmacy customer base doubling and a $3 trillion market cap that makes Hims a rounding error, though FTC scrutiny is a wildcard. Other possible suitors include UnitedHealth, CVS Health, and Pfizer, each facing integration or regulatory hurdles. CEO Andrew Dudum holds super-voting control and recently bought 155,000 shares, signaling no intent to sell, while the company is itself acquiring Eucalyptus in a deal expected to close mid-2026. Private equity could pursue a take-private given fiscal 2026 revenue guidance of $2.80 billion to $3.00 billion and adjusted EBITDA of $275 million to $350 million, but roughly $1 billion in convertible debt poses a leverage obstacle.

Holzer & Holzer, LLC announced an investigation into whether Hims & Hers Health, Inc. complied with federal securities laws. The investigation follows a Federal Trade Commission lawsuit filed on July 29, 2026, alleging the company fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers they will be able to consult with a medical provider to find a treatment that is right for them. Following this news, the price of the company’s stock dropped. The law firm is encouraging investors who purchased Hims & Hers stock and suffered a loss to contact Corey Holzer or Joshua Karr to discuss their legal rights.

Hims & Hers Health shares fell after Reuters reported the U.S. Federal Trade Commission is suing the telehealth company for allegedly sharing users' health data with online advertisers. An FTC spokesperson said the company shared the information despite pledging to protect privacy and also engaged in deceptive billing and cancellation practices. The lawsuit, filed in Los Angeles County and Utah, accuses Hims & Hers of sending user data to advertising firms including Meta and Snap through website interactions and tracking methods. Hims & Hers did not immediately respond to a request for comment.

Hims & Hers Health announced that Chief Accounting Officer Irene Becklund will depart effective October 9, 2026, after more than seven years with the telehealth company. Becklund, who joined as the firm's first controller in 2019, helped guide its transition from a private company to a public corporation through its 2021 IPO and played a key role in recent acquisitions and global expansion. Following her resignation, she will serve as an advisor for a few months to ensure a smooth transition, while CFO Yemi Okupe will assume the CAO responsibilities in the interim. The company said it will begin an executive search for a permanent replacement.

Lowey Dannenberg, P.C. has launched an investigation into Hims & Hers Health, Inc. over allegations that the telehealth company improperly shared and tracked users' private health information. The firm claims Hims & Hers collected and disclosed subscribers' personal data and sensitive health-related responses to third parties without meaningful consent, potentially violating privacy policies and state and federal laws. Affected United States residents who completed a Hims & Hers assessment and are 18 or older may be eligible to recover up to $10,000 in compensation through binding mass arbitration. Individuals can check eligibility and create an account on the case management platform Claim Magic at no cost.

Hims & Hers Health has been assigned a Zacks Rank #5, or Strong Sell, as consensus earnings estimates for the company remain unchanged. The company is expected to post a loss of $0.06 per share for the current quarter, a year-over-year decline of 135.3%, while the full-year estimate stands at a loss of $0.23 per share, down 143.4% from the prior year. For the next fiscal year, the consensus estimate is $0.50 per share, representing a 320.9% increase, but this figure has also held steady over the past 30 days. Revenue projections show growth, with the current quarter estimate at $689.49 million, up 26.6% year-over-year, and full-year estimates of $2.9 billion and $3.4 billion for the current and next fiscal years, respectively. The stock has returned 26% over the past month, outperforming the broader market, but its valuation grade of F suggests it is trading at a premium to peers.

GoodRx reported first-quarter revenues of $194 million, down 4.4% year on year, exceeding analysts' expectations by 4.9%. The company also provided full-year revenue guidance that slightly topped estimates. Among the seven healthcare technology stocks tracked, GoodRx posted the slowest revenue growth, while the group overall beat consensus revenue estimates by 1.6% and issued in-line next-quarter guidance. Omnicell delivered the best performance with revenues of $309.9 million, up 14.9% year on year, and Hims & Hers Health was the weakest, with revenues of $608.1 million missing estimates by 1.4%. Astrana Health achieved the fastest revenue growth at 55.6% year on year, and Tandem Diabetes raised its full-year guidance the most among peers.